HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir

K. Theys; J. Vercauteren; J. Snoeck; M. Zazzi; R. J. Camacho; C. Torti; E. Schülter; B. Clotet; A. Sönnerborg; A. De Luca; Andrea De Luca; Z. Grossman; D. Struck; A. M. Vandamme; A. B. Abecasise

doi:10.1128/AAC.01668-12

HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir

K. Theys, J. Vercauteren, J. Snoeck, M. Zazzi, R. J. Camacho, C. Torti, E. Schülter, B. Clotet, A. Sönnerborg, A. De Luca, Andrea De Luca, Z. Grossman, D. Struck, A. M. Vandamme, A. B. Abecasise

Università Cattolica del Sacro Cuore

Risultato della ricerca: Contributo in rivista › Articolo in rivista

32 Citazioni (Scopus)

Abstract

Subtype-dependent selection of HIV-1 reverse transcriptase resistance mutation K65R was previously observed in cell culture and small clinical investigations. We compared K65R prevalence across subtypes A, B, C, F, G, and CRF02_AG separately in a cohort of 3,076 patients on combination therapy including tenofovir. K65R selection was significantly higher in HIV-1 subtype C. This could not be explained by clinical and demographic factors in multivariate analysis, suggesting subtype sequence-specific K65R pathways.

Lingua originale	English
pagine (da-a)	1053-1056
Numero di pagine	4
Rivista	Antimicrobial Agents and Chemotherapy
Volume	57
DOI	https://doi.org/10.1128/AAC.01668-12
Stato di pubblicazione	Pubblicato - 2013

Keywords

mutation
subtype

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1128/AAC.01668-12

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Theys, K., Vercauteren, J., Snoeck, J., Zazzi, M., Camacho, R. J., Torti, C., Schülter, E., Clotet, B., Sönnerborg, A., De Luca, A., De Luca, A., Grossman, Z., Struck, D., Vandamme, A. M., & Abecasise, A. B. (2013). HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir. Antimicrobial Agents and Chemotherapy, 57, 1053-1056. https://doi.org/10.1128/AAC.01668-12

@article{f9479848579c47afbf0d2df9f8893134,

title = "HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir",

abstract = "Subtype-dependent selection of HIV-1 reverse transcriptase resistance mutation K65R was previously observed in cell culture and small clinical investigations. We compared K65R prevalence across subtypes A, B, C, F, G, and CRF02_AG separately in a cohort of 3,076 patients on combination therapy including tenofovir. K65R selection was significantly higher in HIV-1 subtype C. This could not be explained by clinical and demographic factors in multivariate analysis, suggesting subtype sequence-specific K65R pathways.",

keywords = "mutation, subtype, mutation, subtype",

author = "K. Theys and J. Vercauteren and J. Snoeck and M. Zazzi and Camacho, {R. J.} and C. Torti and E. Sch{\"u}lter and B. Clotet and A. S{\"o}nnerborg and {De Luca}, A. and {De Luca}, Andrea and Z. Grossman and D. Struck and Vandamme, {A. M.} and Abecasise, {A. B.}",

year = "2013",

doi = "10.1128/AAC.01668-12",

language = "English",

volume = "57",

pages = "1053--1056",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology:PO Box 11127:Birmingham, AL 35201:(800)633-4931, (205)995-1567, EMAIL: asm.nonmembers.subs@ebsco.com, INTERNET: http://www.asm.org, Fax: (205)995-1588",

}

Theys, K, Vercauteren, J, Snoeck, J, Zazzi, M, Camacho, RJ, Torti, C, Schülter, E, Clotet, B, Sönnerborg, A, De Luca, A, De Luca, A, Grossman, Z, Struck, D, Vandamme, AM & Abecasise, AB 2013, 'HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir', Antimicrobial Agents and Chemotherapy, vol. 57, pagg. 1053-1056. https://doi.org/10.1128/AAC.01668-12

TY - JOUR

T1 - HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir

AU - Theys, K.

AU - Vercauteren, J.

AU - Snoeck, J.

AU - Zazzi, M.

AU - Camacho, R. J.

AU - Torti, C.

AU - Schülter, E.

AU - Clotet, B.

AU - Sönnerborg, A.

AU - De Luca, A.

AU - De Luca, Andrea

AU - Grossman, Z.

AU - Struck, D.

AU - Vandamme, A. M.

AU - Abecasise, A. B.

PY - 2013

Y1 - 2013

N2 - Subtype-dependent selection of HIV-1 reverse transcriptase resistance mutation K65R was previously observed in cell culture and small clinical investigations. We compared K65R prevalence across subtypes A, B, C, F, G, and CRF02_AG separately in a cohort of 3,076 patients on combination therapy including tenofovir. K65R selection was significantly higher in HIV-1 subtype C. This could not be explained by clinical and demographic factors in multivariate analysis, suggesting subtype sequence-specific K65R pathways.

AB - Subtype-dependent selection of HIV-1 reverse transcriptase resistance mutation K65R was previously observed in cell culture and small clinical investigations. We compared K65R prevalence across subtypes A, B, C, F, G, and CRF02_AG separately in a cohort of 3,076 patients on combination therapy including tenofovir. K65R selection was significantly higher in HIV-1 subtype C. This could not be explained by clinical and demographic factors in multivariate analysis, suggesting subtype sequence-specific K65R pathways.

KW - mutation

KW - subtype

KW - mutation

KW - subtype

UR - http://hdl.handle.net/10807/40415

U2 - 10.1128/AAC.01668-12

DO - 10.1128/AAC.01668-12

M3 - Article

SN - 0066-4804

VL - 57

SP - 1053

EP - 1056

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

ER -

HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo